Literature DB >> 15046258

Chromatin remodeling and modification during HIV-1 Tat-activated transcription.

Anne Pumfery1, Longwen Deng, Anil Maddukuri, Cynthia de la Fuente, Hong Li, John D Wade, Paul Lambert, Ajit Kumar, Fatah Kashanchi.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) is the etiologic agent of AIDS. Following entry into the host cell, the viral RNA is reverse transcribed into DNA and subsequently integrated into the host genome as a chromatin template. Chromatin structure may be responsible for silencing retroviral gene expression. Transcriptional activation occurs after ATP-dependent chromatin remodeling complexes alter chromatin structure and positioning of nucleosomes. Histone acetyltransferases (HATs), histone deacetylases (HDACs), kinases, and methyltransferases (HMTs), covalently modify nucleosomes by adding or removing chemical moieties in the N-terminal tails of histones. Recent advances have indicated that HIV-1 encoded proteins interact with chromatin remodeling complexes and histone modifying enzymes, implying that chromatin remodeling plays an important role in the HIV-1 life cycle. Nucleosomes are positioned on the HIV-1 LTR and are barriers to transcription. Following cellular activation, these nucleosomes are modified and repositioned allowing for activation of viral gene expression. Tat recruits various HATs to the HIV-1 promoter region and can also be acetylated by some of these enzymes. Unmodified Tat is involved in binding to the CBP/p300 and cdk9/cyclin T complexes and facilitates transcription initiation. Acetylated Tat dissociates from the TAR RNA structure and recruits bromodomain-containing chromatin modifying complexes such as p/CAF and SWI/SNF to facilitate transcription elongation. This review summarizes our current knowledge and understanding of chromatin remodeling complexes and their regulation of HIV-1 replication, and highlights the important contributions HIV-1 research has made to further our understanding of the transcription process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15046258     DOI: 10.2174/1570162033485186

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  35 in total

1.  Targeting of histone acetyltransferase p300 by cyclopentenone prostaglandin Δ(12)-PGJ(2) through covalent binding to Cys(1438).

Authors:  Kodihalli C Ravindra; Vivek Narayan; Gerald H Lushington; Blake R Peterson; K Sandeep Prabhu
Journal:  Chem Res Toxicol       Date:  2011-12-16       Impact factor: 3.739

2.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 3.  Functional roles of HIV-1 Tat protein in the nucleus.

Authors:  Yana R Musinova; Eugene V Sheval; Carla Dib; Diego Germini; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2015-10-27       Impact factor: 9.261

4.  Radical acceleration of nuclear reprogramming by chromatin remodeling with the transactivation domain of MyoD.

Authors:  Hiroyuki Hirai; Tetsuya Tani; Nobuko Katoku-Kikyo; Steven Kellner; Peter Karian; Meri Firpo; Nobuaki Kikyo
Journal:  Stem Cells       Date:  2011-09       Impact factor: 6.277

5.  NF-kappaB-repressing factor inhibits elongation of human immunodeficiency virus type 1 transcription by DRB sensitivity-inducing factor.

Authors:  Ursula Dreikhausen; Kirsten Hiebenthal-Millow; Myriam Bartels; Klaus Resch; Mahtab Nourbakhsh
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.

Authors:  Reem Berro; Kylene Kehn; Cynthia de la Fuente; Anne Pumfery; Richard Adair; John Wade; Anamaris M Colberg-Poley; John Hiscott; Fatah Kashanchi
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 7.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

8.  The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients.

Authors:  Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Rebecca Easley; Zachary Klase; Chenglong Liu; Mary Young; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-07-06       Impact factor: 2.250

9.  Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication.

Authors:  Masha Sorin; Jennifer Cano; Supratik Das; Sheeba Mathew; Xuhong Wu; Kelvin P Davies; Xuanling Shi; S-W Grace Cheng; David Ott; Ganjam V Kalpana
Journal:  PLoS Pathog       Date:  2009-06-05       Impact factor: 6.823

10.  In vitro nuclear interactome of the HIV-1 Tat protein.

Authors:  Virginie W Gautier; Lili Gu; Niaobh O'Donoghue; Stephen Pennington; Noreen Sheehy; William W Hall
Journal:  Retrovirology       Date:  2009-05-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.